Cantor Fitzgerald Predicts Reduced Earnings for Codexis

Key Points

• Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimate for Codexis to ($0.68) per share, down from the previous estimate of ($0.62).
• In its latest quarterly earnings report, Codexis posted an EPS of ($0.16), surpassing the consensus estimate of ($0.17) and recording revenue of $15.33 million.
• Despite the downgrade, Wall Street Zen upgraded Codexis shares from a "strong sell" rating to a "hold" rating, indicating a shift in market sentiment.

Codexis, Inc. (NASDAQ:CDXS - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Codexis in a report issued on Thursday, August 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of ($0.68) for the year, down from their prior estimate of ($0.62). The consensus estimate for Codexis' current full-year earnings is ($0.77) per share. Cantor Fitzgerald also issued estimates for Codexis' FY2026 earnings at ($0.61) EPS.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. Codexis had a negative return on equity of 105.83% and a negative net margin of 113.67%.The business had revenue of $15.33 million during the quarter, compared to analysts' expectations of $14.18 million.

Separately, Wall Street Zen raised shares of Codexis from a "strong sell" rating to a "hold" rating in a report on Saturday, August 16th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Codexis Stock Performance

Codexis stock traded up $0.06 during midday trading on Monday, reaching $2.88. 1,218,144 shares of the company's stock were exchanged, compared to its average volume of 1,208,051. Codexis has a 52 week low of $1.90 and a 52 week high of $6.08. The company has a debt-to-equity ratio of 0.71, a quick ratio of 5.70 and a current ratio of 5.82. The firm has a market cap of $259.98 million, a price-to-earnings ratio of -3.47 and a beta of 2.54. The stock's 50-day simple moving average is $2.77 and its 200 day simple moving average is $2.77.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. boosted its holdings in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,783 shares during the period. Baillie Gifford & Co. boosted its holdings in Codexis by 0.3% in the 1st quarter. Baillie Gifford & Co. now owns 1,699,644 shares of the biotechnology company's stock valued at $4,572,000 after purchasing an additional 5,619 shares during the period. Bridgeway Capital Management LLC boosted its holdings in Codexis by 6.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 100,908 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 6,300 shares during the period. Two Sigma Investments LP boosted its holdings in Codexis by 2.5% in the 4th quarter. Two Sigma Investments LP now owns 263,218 shares of the biotechnology company's stock valued at $1,256,000 after purchasing an additional 6,397 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Codexis by 19.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,606 shares of the biotechnology company's stock valued at $218,000 after purchasing an additional 7,384 shares during the period. 78.54% of the stock is owned by institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.